Outcomes of Definitive Radiotherapy for Bladder Cancer

NCT07503795 | Not Yet Recruiting DMC FDA Device

• 1 other identifier: Soh-Med-25-12___15PD
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer

Conditions

Bladder Cancer (BC)

Outcome Measures

Primary Outcomes (3)

• overall survival, it is defined as time from initiation of treatment till death due to any cause or last date for follow up

  one and two year

• bladder intact events free survival , which is the time from initiation of radical ttt till occurrence of bladder recurrence

  one and two year

• disease free survival , it is time from starting radical ttt till occurrance of 1st recurrence or distant metastasis

  one and two years

Secondary Outcomes (1)

• adverse events , it is treatment related toxicity and side effects

  one year

Study Arms (1)

patient with bladder cancer recieving radiotherapy and the treatment related events

Radiation: Radiotherapy followed by chemotherapy

Interventions

Radiotherapy followed by chemotherapy RADIATION

it is observational study for patient recieved defentive radiotherapy

patient with bladder cancer recieving radiotherapy and the treatment related events

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Medical records of all cancer urinary bladder patients will be examined retrospectively. Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy (≥50 Gy to bladder/pelvis); complete treatment records available.

You may qualify if:

• Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy

You may not qualify if:

• Palliative radiotherapy only; prior radical cystectomy; or incomplete follow-up data.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag University Hospitals

Sohag, Egypt

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Central Study Contacts

heba elsagheer

CONTACT

0201062162612; hebaelsagheer@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: proffesor clinical oncology

Study Record Dates

• First Submitted: February 5, 2026
• First Posted: March 31, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): June 1, 2027
• Last Updated: March 31, 2026

Record last verified: 2026-02

Locations

EG (1)